Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy

Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy

Background: Abemaciclib was recently approved by the European Medicines Agency in combination with adjuvant endocrine therapy (ET) for adult patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2−), node-positive early breast cancer (EBC) at high risk...

Full description

Bibliographic Details
Main Authors: Alison Davie, Sory Traoré, Massimo Giovannitti, Giuseppe Pompilio, Mark Lambton, Esra Cakar, Anuja Chatterjee
Format: Article
Language:English
Published: AboutScience Srl 2023-09-01
Series:Global & Regional Health Technology Assessment
Subjects:
Abemaciclib
Cost-effectiveness
Early breast cancer
Endocrine therapy
HER2−
HR
Online Access:https://journals.aboutscience.eu/index.php/grhta/article/view/2561

Internet

https://journals.aboutscience.eu/index.php/grhta/article/view/2561

Similar Items